ICO - Site René Gauducheau

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Colorectal cancer2 trials
• Lung cancer2 trials
• Bladder cancer1 trial
• Cervical cancer1 trial
• Childhood cancers1 trial
• Liver and biliary tract cancer1 trial
• Neuroendocrine tumours1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 23 trials
• Phase 33 trials
• Phase 1/22 trials
• Phase 11 trial

Status

• Completed6 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial
• Recruiting1 trial
• Suspended1 trial

Lead sponsor

• Hoffmann-La Roche3 trials
• UNICANCER3 trials
• Menarini Group2 trials
• Daiichi Sankyo1 trial
• Dragonfly Therapeutics1 trial
• and 2 more

Running trials

• Recruiting

  A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

  NCT06541652· Federation Francophone de Cancerologie Digestive· Source

  Contact: TIMOTHEE VIGNAUD, DR

• Recruiting

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

  NCT04931342· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

  NCT03438552· UNICANCER· Source

• Active, not recruiting

  Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

  NCT03333356· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Liver and biliary tract cancer1 recruiting
• Neuroendocrine tumours1 recruiting

Closed trials

• Completed

  MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

  NCT04495621· Phase 1/2· Menarini Group· Source

• Completed

  A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

  NCT04300647· Phase 2· Hoffmann-La Roche· Source

• Completed

  Study of DF1001 in Patients With Advanced Solid Tumors

  NCT04143711· Phase 1/2· Dragonfly Therapeutics· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

  NCT03767335· Phase 1· Menarini Group· Source

• Completed

  M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03631706· Phase 3· EMD Serono Research & Development Institute, Inc.· Source